Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Expected to Post Quarterly Sales of $5.65 Million

Brokerages expect Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) to post $5.65 million in sales for the current quarter, according to Zacks. Five analysts have provided estimates for Syros Pharmaceuticals’ earnings. The highest sales estimate is $6.00 million and the lowest is $5.00 million. Syros Pharmaceuticals posted sales of $5.70 million in the same quarter last year, which suggests a negative year over year growth rate of 0.9%. The firm is scheduled to report its next earnings results on Thursday, March 3rd.

According to Zacks, analysts expect that Syros Pharmaceuticals will report full year sales of $21.32 million for the current year, with estimates ranging from $20.69 million to $21.69 million. For the next year, analysts anticipate that the business will report sales of $17.79 million, with estimates ranging from $8.40 million to $21.40 million. Zacks’ sales averages are a mean average based on a survey of analysts that cover Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its earnings results on Friday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.03. Syros Pharmaceuticals had a negative net margin of 434.32% and a negative return on equity of 77.65%. During the same period in the prior year, the business posted ($0.43) earnings per share.

A number of research firms have recently weighed in on SYRS. JMP Securities restated a “buy” rating and set a $20.00 price target on shares of Syros Pharmaceuticals in a report on Tuesday, September 21st. HC Wainwright restated a “buy” rating on shares of Syros Pharmaceuticals in a report on Monday, November 8th. Roth Capital raised their price target on shares of Syros Pharmaceuticals from $20.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, September 23rd. Finally, Zacks Investment Research upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, November 10th.

SYRS stock traded up $0.08 during midday trading on Thursday, reaching $4.13. The company had a trading volume of 408,990 shares, compared to its average volume of 830,844. Syros Pharmaceuticals has a 1 year low of $3.70 and a 1 year high of $15.65. The company has a current ratio of 5.13, a quick ratio of 6.74 and a debt-to-equity ratio of 0.38. The company has a market capitalization of $255.84 million, a P/E ratio of -2.55 and a beta of 1.85. The company has a 50 day moving average of $4.40 and a two-hundred day moving average of $4.93.

A number of large investors have recently bought and sold shares of the stock. FMR LLC grew its stake in Syros Pharmaceuticals by 0.4% in the 2nd quarter. FMR LLC now owns 9,047,965 shares of the company’s stock valued at $49,311,000 after buying an additional 32,853 shares during the last quarter. BlackRock Inc. grew its stake in Syros Pharmaceuticals by 7.1% in the 2nd quarter. BlackRock Inc. now owns 4,463,356 shares of the company’s stock valued at $24,325,000 after buying an additional 295,392 shares during the last quarter. Vanguard Group Inc. grew its position in Syros Pharmaceuticals by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 2,775,576 shares of the company’s stock worth $15,127,000 after purchasing an additional 43,152 shares during the last quarter. Omega Fund Management LLC grew its position in Syros Pharmaceuticals by 45.6% in the 2nd quarter. Omega Fund Management LLC now owns 2,274,831 shares of the company’s stock worth $12,398,000 after purchasing an additional 712,331 shares during the last quarter. Finally, Artal Group S.A. grew its position in Syros Pharmaceuticals by 17.6% in the 3rd quarter. Artal Group S.A. now owns 2,000,000 shares of the company’s stock worth $8,940,000 after purchasing an additional 300,000 shares during the last quarter. Institutional investors and hedge funds own 82.18% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Read More: LIBOR

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.